Compare CDLX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | LUNG |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 72.2M |
| IPO Year | 2018 | 2020 |
| Metric | CDLX | LUNG |
|---|---|---|
| Price | $0.87 | $1.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.25 | ★ $6.81 |
| AVG Volume (30 Days) | ★ 689.8K | 355.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $278,298,000.00 | $83,789,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $0.80 | $1.31 |
| 52 Week High | $3.28 | $8.72 |
| Indicator | CDLX | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 47.44 |
| Support Level | $0.83 | $1.51 |
| Resistance Level | $1.04 | $1.69 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 18.90 | 68.85 |
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.